Denmark confirms excessive-pricing decision

Denmark’s Competition Appeals Tribunal has confirmed findings by the country’s antitrust authority that drug distributor CD Pharma abused its dominant position in the market for the distribution of a stimulant drug by raising its price by 2000%.

Unlock unlimited access to all Global Competition Review content